A
system for detecting the presence of
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a biological sample includes a sampling device, a lysing chamber, a
NASBA fluidic network, and an analytical instrument. The sampling device is configured to contain a sample containing a
pathogen target sequence for SARS-CoV-2. The lysing chamber is configured to be in fluid communication with the sampling device to receive the sample. The is lysing chamber is configured to lyse the sample into a lysate. The
NASBA fluidic network is configured to be in fluid communication with the lysing chamber to receive the lysate. The
NASBA fluidic network includes an
enzyme, a
forward primer, and a
reverse primer for amplifying a predetermined genetic sequence in the
pathogen target sequence contained within the lysate. The
forward primer has the
oligonucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, and SEQ ID NO: 17. The
reverse primer has the
oligonucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, and SEQ ID NO: 18. A
molecular beacon is configured to attach to the
pathogen target sequence. The
beacon has the
oligonucleotide sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15, and SEQ ID NO: 19 and a
fluorophore. The analytical instrument is configured to excite the
beacon when the
molecular beacon is attached to the pathogen target sequence to
signal a presence of the pathogen target sequence.